Alvotech (NASDAQ:ALVO) Stock Rating Cut to Strong Sell at Zacks Research

Posted by Brenda Bartman on Oct 22nd, 2026

Alvotech (NASDAQ:ALVO – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

A number of other brokerages also recently issued reports on ALVO. Evercore initiated coverage on Alvotech in a research report on Friday, August 14th. They set an “outperform” rating on the stock. Bank of America began coverage on Alvotech in a research note on Monday, August 24th. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings raised Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Barclays upgraded Alvotech from an “underweight” rating to an “overweight” rating and upped their target price for the company from $4.00 to $8.00 in a research report on Wednesday, September 16th. Finally, UBS Group set a $8.00 target price on Alvotech in a research report on Wednesday, September 16th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.50.

Check Out Our Latest Stock Analysis on Alvotech

Alvotech Price Performance

NASDAQ:ALVO opened at $5.13 on Tuesday. Alvotech has a one year low of $2.94 and a one year high of $8.50. The company has a market cap of $1.55 billion, a P/E ratio of -8.41 and a beta of 0.20. The firm’s fifty day moving average price is $5.24 and its two-hundred day moving average price is $4.15.

Alvotech (NASDAQ:ALVO – Get Free Report) last posted its earnings results on Thursday, August 20th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The firm had revenue of $106.00 million during the quarter, compared to the consensus estimate of $103.00 million. As a group, equities research analysts expect that Alvotech will post -0.01 earnings per share for the current year.

Hedge Funds Weigh In On Alvotech

Several hedge funds and other institutional investors have recently made changes to their positions in ALVO. Citadel Advisors LLC acquired a new stake in shares of Alvotech during the 2nd quarter worth approximately $6,376,000. Renaissance Technologies LLC increased its stake in Alvotech by 146.9% in the first quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock valued at $217,000 after acquiring an additional 37,600 shares during the last quarter. Finally, Ulland Investment Advisors LLC increased its stake in Alvotech by 5.0% in the third quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock valued at $667,000 after acquiring an additional 5,500 shares during the last quarter.

Trending Headlines about Alvotech

Here are the key news stories impacting Alvotech this week:

Positive Sentiment: The FDA approved Alvotech’s Process 2.0 for SIMLANDI manufacturing at its Reykjavik facility. The process more than doubles drug-substance output per batch while maintaining product quality, safety and efficacy. Alvotech receives FDA approval for new SIMLANDI manufacturing process
Positive Sentiment: The higher-yield process allows Alvotech to produce the same amount of drug substance in fewer batches, freeing manufacturing capacity for other biosimilars and improving its ability to meet partner demand. The approval follows a separate recent FDA authorization for additional manufacturing capacity. Alvotech shares rise after FDA approves Simlandi manufacturing process
Neutral Sentiment: The manufacturing approval strengthens Alvotech’s operational position and supply reliability, but the company’s broader financial benefit will depend on commercial demand, pricing, execution and the performance of its biosimilar portfolio. Alvotech wins FDA approval for manufacturing upgrade
Negative Sentiment: Zacks added ALVO to its Rank #5, or “Strong Sell,” list. The ranking may weigh on sentiment by signaling unfavorable expectations relative to Zacks’ quantitative criteria, offsetting some of the optimism from the FDA announcement. New Strong Sell stocks for October 21st

About Alvotech

(Get Free Report)

Alvotech is a biotechnology company headquartered in Reykjavík, Iceland, focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to already approved reference medicines and are intended to expand patient access to complex treatments at potentially lower costs.

The company uses an integrated research, development and manufacturing model and concentrates on therapeutic areas including immunology, ophthalmology, oncology and bone health.